

INVESTOR WEBINAR

Perth, Australia: Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, is please to invite shareholders and interested investors to attend an upcoming investor webinar. The webinar will be presented by Argenica’s CEO and Managing Director, Dr Liz Dallimore, who will provide a clinical and operational update, addressing the path forward for the Company’s lead neuroprotective drug candidate, ARG-007 (xaranetide).

Investor Webinar 11am AEST Thursday 11th June, 2026

You are invited to register using the link below:

https://us06web.zoom.us/webinar/register/WN_cCDrNxfRR8KoBKV4Qi1BqA

Participants may submit questions at registration or during the session

Enquiries

Liz Dallimore, CEO/Managing Director, Argenica Therapeutics | Email:

info@argenica.com.au

Matt Worner, Investor Relations, VECTOR Advisors | Email: mworner@vectoradvisors.au

This announcement has been approved for release by Argenica’s Managing Director, Liz Dallimore.

ABOUT ARGENICA

Argenica Therapeutics Limited (ASX: AGN) is a clinical-stage biotechnology company developing innovative neuroprotective therapeutics to improve outcomes for patients following stroke and other acute neurological injuries. The Company’s lead drug candidate, ARG-007 (xaranetide), is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischemic event. With a strong scientific foundation and a clear clinical development pathway, Argenica is focused on advancing novel treatments that have the potential to significantly improve patient recovery and transform the standard of care in acute neurology.

For personal use only